Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2025-12-18 Report Publication Anno…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is a short list of upcoming dates for financial reporting and meetings (Financial calendar). It does not contain the actual reports or meeting materials themselves, but rather serves as an announcement of when these events will occur. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of company reports is classified as a Report Publication Announcement (RPA).
2025-12-18 English
Finansiell kalender
Report Publication Announcement Classification · 99% confidence The document is a 'Finansiell kalender' (Financial Calendar) for Arctic Bioscience AS, which lists the scheduled dates for the release of the annual report, half-year report, and the annual general meeting for the year 2026. Since it is a short announcement regarding the timing and publication of future reports, it falls under the category of a Report Publication Announcement.
2025-12-18 Norwegian
Arctic Bioscience - Share capital increase registered
Share Issue/Capital Change Classification · 100% confidence The document announces the registration of a share capital increase with the Norwegian Register of Business Enterprises following the exercise of debt conversion rights. This directly relates to changes in the company's capital structure and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-12-17 English
Arctic Bioscience - Registrert aksjekapitalforhøyelse
Share Issue/Capital Change Classification · 100% confidence The document announces the registration of an increase in share capital following a debt conversion. This is a direct announcement of a change in the company's capital structure and share count, which falls under the category of share issues or capital changes.
2025-12-17 Norwegian
Arctic Bioscience - Styrets godkjennelse av kapitaløkning relatert til gjeldskonvertering - Attachment: 20251212_Statment_from_the_BoD_of_ABS.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Statement regarding capital increase' (Redegjørelse i anledning kapitalforhøyelse) issued by the board of Arctic Bioscience AS. It details the conversion of a convertible loan into equity (share capital increase) and includes the mandatory auditor's statement (Uttalelse om redegjørelse) required by Norwegian law (aksjeloven § 2-6). This document is a direct announcement of a capital change and share issuance resulting from debt conversion, which falls under the 'Share Issue/Capital Change' category.
2025-12-12 Norwegian
Arctic Bioscience - Board approval of share capital increase related to conversion of debt - Attachment: 20251212_Statment_from_the_BoD_of_ABS.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Statement regarding capital increase' (Redegjørelse i anledning kapitalforhøyelse) issued by the board of Arctic Bioscience AS. It details the conversion of a convertible loan into equity (share capital) and includes the mandatory auditor's statement (Uttalelse om redegjørelse) required by the Norwegian Private Limited Liability Companies Act. Since this document specifically details the issuance of new shares and the change in capital structure, it falls under the 'Share Issue/Capital Change' category.
2025-12-12 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.